ReviewClinical & developmental immunology2013
Interleukin-19 in breast cancer.
Review in Clinical & developmental immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin.Breast cancer research and treatment · 2021Trial
- A Literature Review of Interleukins in the Development and Treatment of Breast Cancer.International journal of molecular sciences · 2026Review
- Integrative machine learning models reveal immune and metabolic signatures predictive of colorectal cancer prognosis.Discover oncology · 2026Article
- Phenotypic alterations in the immune system and tolerance induction in tumor-draining lymph nodes.Iranian journal of basic medical sciences · 2026Review
- IL-19 suppresses Hippo signaling via modulating YAP1 phosphorylation in osteoarthritis.Frontiers in immunology · 2025Article
- Elucidation of interleukin-19 as a therapeutic target for breast cancer by computational analysis and experimental validation.Saudi journal of biological sciences · 2023Article
- Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma.Journal of immunology research · 2023Article
- Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer.Frontiers in oncology · 2023Review
- Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects.Archives of gynecology and obstetrics · 2022Article
- Comparison of TNF-α and IL-19 concentrations at different stages of breast cancer.Journal of medicine and life · 2022Article
- Effect of Microbiota in the Development of Breast Cancer.Archives of Razi Institute · 2021Article
- Interleukins in cancer: from biology to therapy.Nature reviews. Cancer · 2021Review
- TYK2: An Upstream Kinase of STATs in Cancer.Cancers · 2019Review
- Regulation Mechanism of Long Noncoding RNAs in Colon Cancer Development and Progression.Yonsei medical journal · 2019Review
- Blocking IL-19 Signaling Ameliorates Allergen-Induced Airway Inflammation.Frontiers in immunology · 2019Article
- Interleukins Associated with Breast Cancer.Cureus · 2018Review
- An Exploratory Search for Potential Molecular Targets Responsive to the ProbioticFrontiers in microbiology · 2018Article
- Identification of Prognostic Genes and Pathways in Lung Adenocarcinoma Using a Bayesian Approach.Cancer informatics · 2017Article
- Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.BMC cancer · 2016Article
- Regulation of IL-20 Expression by Estradiol through KMT2B-Mediated Epigenetic Modification.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory cytokines within the tumor microenvironment are linked to progression in breast cancer. Interleukin- (IL-) 19, part of the IL-10 family, contributes to a range of diseases and disorders, such as asthma, endotoxic shock, uremia, psoriasis, and rheumatoid arthritis. IL-19 is expressed in several types of tumor cells, especially in squamous cell carcinoma of the skin, tongue, esophagus, and lung and invasive duct carcinoma of the breast. In breast cancer, IL-19 expression is correlated with increased mitotic figures, advanced tumor stage, higher metastasis, and poor survival. The mechanisms of IL-19 in breast cancer have recently been explored both in vitro and in vivo. IL-19 has an autocrine effect in breast cancer cells. It directly promotes proliferation and migration and indirectly provides a microenvironment for tumor progression, which suggests that IL-19 is a prognostic marker in breast cancer and that antagonizing IL-19 may have therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.